Home » Topics » Gastrointestinal, BioWorld Science

Gastrointestinal, BioWorld Science
RSS

Patient dosing begins in phase I study of first anti-HCV ribozyme therapy

Feb. 17, 2000

Vion licenses potential HBV/HIV therapy to Achillion

Feb. 14, 2000

FDA to review Schering-Plough's BLA for PEG-Intron

Feb. 11, 2000

FDA approves Lotronex for IBS in women

Feb. 10, 2000

AxyS enters drug design agreement with Bristol-Myers Squibb

Feb. 9, 2000

Gastric antisecretory agents from KRICT superior to omeprazole in vitro and in vivo

Feb. 8, 2000

FDA approves tablet formulation of Protonix for erosive esophagitis

Feb. 7, 2000

New oral IBD treatment targets macrophages and microfold cells

Feb. 1, 2000

SciClone initiates phase II study of Zadaxin in hepatitis B

Jan. 28, 2000

U.S. patent for HCV vaccine granted to Innogenetics

Jan. 27, 2000

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...